Neumora Therapeutics Income Statement (2022-2026) | NMRA

Income Statement Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter) 22.55M23.52M29.48M32.77M41.60M38.86M45.76M48.63M60.63M45.91M52.15M38.72M40.52M44.67M38.60M
Selling, General & Administrative (Quarter) 8.05M7.20M9.68M9.29M15.26M11.24M14.32M15.19M16.02M17.01M18.79M15.32M12.18M13.81M14.27M
Other Operating Expenses (Quarter) 63.90M5.00M
Operating Expenses (Quarter) 30.60M30.72M39.17M42.06M56.86M114.00M60.07M63.82M76.65M62.92M70.94M54.04M57.70M58.48M52.86M
Operating Income (Quarter) -30.60M-30.72M-39.17M-42.06M-56.86M-114.00M-60.07M-63.82M-76.65M-62.92M-70.94M-54.04M-57.70M-58.48M-52.86M
EBIT (Quarter) -30.60M-30.72M-39.17M-42.06M-56.86M-114.00M-60.07M-63.82M-76.65M-62.92M-70.94M-54.04M-57.70M-58.48M-52.86M
Non-operating items
Interest & Investment Income (Quarter) 1.41M2.29M3.57M3.56M3.84M5.65M6.37M5.27M4.21M4.09M3.07M1.81M1.69M1.33M1.23M
Other Non Operating Income (Quarter) -0.15M0.29M-0.03M-0.04M-0.00M-0.10M-0.01M-0.02M-0.06M0.01M-0.03M-0.48M0.01M-0.27M0.06M
Non Operating Income (Quarter) 1.26M-1.99M-0.03M-0.04M3.84M5.54M6.35M5.25M4.15M0.01M-0.03M1.33M0.01M-6.09M-0.56M
Net income details
EBT (Quarter) -29.20M-28.43M-35.60M-38.54M-53.03M-108.46M-53.72M-58.58M-72.49M-58.82M-67.89M-52.71M-56.76M-59.45M-53.43M
Tax Provisions (Quarter) 0.12M0.05M0.10M0.03M0.03M
Profit After Tax (Quarter) -29.34M-28.15M-35.62M-38.54M-53.03M-108.73M-53.72M-58.70M-72.55M-58.82M-67.99M-52.73M-56.76M-59.45M-53.46M
Income from Continuing Operations (Quarter) -29.20M-28.43M-35.60M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.82M-67.99M-52.73M-56.76M-59.45M-53.46M
Consolidated Net Income (Quarter) -29.20M-28.43M-35.60M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.82M-67.99M-52.73M-56.76M-59.45M-53.46M
Income towards Parent Company (Quarter) -29.20M-28.43M-35.60M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.82M-67.99M-52.73M-56.76M-59.45M-53.46M
Net Income towards Common Stockholders (Quarter) -29.20M-28.43M-35.60M-38.54M-53.03M-108.46M-53.72M-58.70M-72.55M-58.82M-67.99M-52.73M-56.76M-59.45M-53.46M
Additional items
EPS (Basic) (Quarter) -1.06-0.98-1.22-1.28-1.14-0.04-0.34-0.37-0.45-0.37-0.42-0.33-0.35-0.35-0.30
EPS (Weighted Average and Diluted) (Quarter) -1.06-0.98-1.22-1.28-1.14-0.04-0.34-0.37-0.45-0.37-0.42-0.33-0.35-0.35-0.30
Shares Outstanding (Weighted Average) (Quarter) 27.65M27.21M29.28M29.70M46.69M65.02M157.94M158.98M158.84M159.38M161.45M161.57M161.66M163.39M179.87M
Shares Outstanding (Diluted Average) (Quarter) 27.65M27.21M29.28M30.12M46.69M65.02M157.94M158.98M158.84M159.38M161.45M161.69M161.66M163.39M179.87M
EBITDA (Quarter) -29.63M-27.77M-35.15M-38.69M-52.89M-108.50M-53.79M-58.74M-72.25M-58.86M-68.06M-52.74M-56.73M-59.46M-53.46M
Interest Expenses (Quarter) 0.75M2.04M1.85M
Shares Outstanding (Quarter) 32.59M32.61M32.71M32.82M152.70M158.83M159.36M159.95M160.48M161.71M161.75M161.95M161.95M174.26M182.16M
Tax Rate (Quarter) -0.21-0.07-0.15-0.05-0.06